Strategies to treat PH1 through delivery of the human AGXT complementary DNA with viral vectors have been effective in restoring the metabolic phenotype in a mouse model [33] and AGT expression in a cell model of PH1 [49]. This evidence concerns the gene AGXT and primary hyperoxaluria type 1.